• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A cross-sectional study within a prospective National Institutes of Health cohort has established that bronchiectasis affects more than a quarter of individuals with inborn errors of immunity, demonstrating that irreversible airway destruction drives substantial cardiopulmonary morbidity and mortality across diverse genetic conditions. Published in the Journal of Clinical Immunology, the investigation evaluated pediatric and adult patients undergoing genomic sequencing and chest computed tomography to determine prevalence, identify independent predictors, and evaluate physiological complications. Structural lung damage in inborn errors of immunity represents a severe consequence driven by recurrent bacterial infections, impaired epithelial and mucociliary clearance, chronic inflammation, and progressive remodeling—a destructive cycle termed the vicious vortex. Comprehensive assessments integrating molecular diagnoses with multi-system cardiopulmonary evaluations have historically remained sparse. By analyzing genetically characterized participants across dozens of diagnostic categories, the study demonstrates that bronchiectasis is not restricted to classic antibody deficiencies but spans multiple immunological classes, carrying profound implications for routine surveillance, prognosis, and selection for definitive cellular therapies.

The investigation evaluated patients enrolled in protocol NCT03394053, an ongoing prospective study titled The Mechanistic Biology of Primary Immunodeficiency Disorders, approved by the National Institutes of Health Institutional Review Board. Between 2018 and 2024, two hundred twenty-nine children and adults with confirmed or suspected inborn errors of immunity were enrolled under informed consent adhering to the Declaration of Helsinki. To ensure objective ascertainment, the primary inclusion criterion required participants to have undergone clinically indicated or protocol-directed chest computed tomography, yielding an analytical cohort of one hundred thirty-one patients. Among these individuals, sixty percent were male, seventy-six percent were white, and thirty percent presented with immunodeficiencies affecting cellular and humoral immunity. Thirty-three percent remained unclassified due to ambiguous laboratory phenotypes or incomplete molecular resolution. The median age at first study chest computed tomography was twenty point three years, with an interquartile range of nine point nine to thirty-three years. Thirty-one distinct molecular entities were cataloged, with pathogenic variants in RAG1 representing fourteen percent of the cohort.

Participants were classified using the 2024 International Union of Immunological Societies guidelines, which organize inborn errors of immunity into ten major diagnostic categories based on genetic mutations and laboratory phenotypes. Although current immunological taxonomy recognizes five hundred fifty-five distinct inborn errors of immunity and seventeen phenocopies linked to approximately five hundred genes, only twelve conditions within the official classification explicitly highlight bronchiectasis as a recognized feature. Genomic testing in the cohort was performed via Sanger, whole exome, or whole genome sequencing under the centralized sequencing protocol of the National Institute of Allergy and Infectious Diseases. Identified variants were curated to determine the primary lesion driving immune dysfunction, while documenting secondary heterozygous variants, such as CFTR alterations, that could confer additive susceptibility to respiratory disease. While more than two hundred fifty novel immune genes were discovered over the preceding decade, phenotypic documentation of chronic pulmonary disease has lagged behind molecular discovery, leaving vital gaps in clinical practice guidelines for vulnerable cohorts.

Ascertainment of bronchiectasis relied upon chest computed tomography images evaluated by radiologists at the National Institutes of Health clinical research center. To ensure strict adherence to non-cystic fibrosis bronchiectasis guidelines, investigators deliberately excluded traction bronchiectasis from their primary definition. Traction bronchiectasis represents bronchial dilatation occurring secondarily to adjacent fibrotic pulmonary parenchyma, typically localizing to peripheral or subpleural regions exhibiting reticulation or honeycombing in interstitial lung disease. By excluding traction-mediated airway changes, the analytical definition focused exclusively on irreversible airway dilatation directly attributable to chronic inflammation and infectious insult. Imaging frequency differed markedly across subgroups: participants diagnosed with bronchiectasis underwent a median of three chest computed tomography scans during the study observation window, with an interquartile range of one to six point five, compared to a median of one scan, with an interquartile range of one to two, among participants without bronchiectasis, a statistically significant difference with a P-value of zero point zero zero three.

Computed tomography revealed widespread thoracic involvement, encompassing parenchymal, vascular, pleural, and mediastinal abnormalities with substantial clinical overlap. Pulmonary nodules were the most frequent abnormality, detected in fifty-five percent of all evaluated patients, followed by ground-glass opacification and lymphadenopathy, each observed in forty percent of participants. A clinical-radiological pattern consistent with granulomatous-lymphocytic interstitial lung disease, defined by concurrent pulmonary nodules, ground-glass opacities, and lymphadenopathy, was identified in sixteen percent of the overall cohort and twenty-nine percent of individuals with bronchiectasis. Morphological patterns of airway dilation included cylindric, varicose, and cystic variations, with spatial distributions ranging from focal segments to multi-lobar and diffuse involvement. Patients with confirmed bronchiectasis exhibited significantly higher frequencies of specific radiological abnormalities compared to counterparts without airway destruction, including tree-in-bud opacities, mucous plugging, nodules, ground-glass attenuation, fibrosis, calcification, and granulomatous-lymphocytic interstitial changes, with all comparative differences reaching statistical significance ranging from P less than zero point zero zero one to P equal to zero point zero three six.

The overall prevalence of radiologically confirmed bronchiectasis within the cohort was twenty-seven percent, with a ninety-five percent confidence interval of nineteen point nine to thirty-four point nine percent. Among thirty-five affected individuals, fifty-one percent were male, thirty-one percent were children, fifty-seven percent originated from North America, and sixty-six percent were white. Forty percent had combined immunodeficiencies affecting cellular and humoral immunity, twenty-nine percent possessed biallelic RAG1 pathogenic variants, and twenty percent were unclassified. Patients with bronchiectasis were significantly older at their first chest computed tomography scan, exhibiting a median age of twenty-five point five years compared to seventeen point six years in those without bronchiectasis, yielding a P-value of zero point zero two six. Older age reflects cumulative lifetime exposure to recurrent pulmonary infections and persistent inflammatory signaling, fitting the genome-exposome model where inherited susceptibility intersects over time with external insults to overwhelm intrinsic tissue repair mechanisms.

Multivariable logistic regression modeling was constructed a priori to assess independent clinical predictors of bronchiectasis while adjusting simultaneously for age, sex, race, and International Union of Immunological Societies diagnostic classification. In the primary model, older age at first chest computed tomography was an independent predictor, with an adjusted odds ratio of one point zero four per year and a ninety-five percent confidence interval of one point zero one to one point zero eight. Diagnostic categories demonstrated strong predictive capacity: patients with combined immunodeficiencies affecting cellular and humoral immunity had an adjusted odds ratio of four point three zero, those with predominantly antibody deficiencies had an adjusted odds ratio of five point eight three, and individuals with diseases of immune dysregulation had an adjusted odds ratio of seven point five six. Subgroup analyses revealed that among pediatric patients, female sex was an independent predictor, conferring an adjusted odds ratio of five point seven seven. Among adult participants, predominantly antibody deficiency remained the dominant predictor, yielding an adjusted odds ratio of six point nine two.

Cardiopulmonary investigations demonstrated extensive, statistically significant physiological impairment across every measured domain among patients with bronchiectasis compared to unaffected participants. Testing incorporated spirometry, lung volumes, diffusing capacity for carbon monoxide, six-minute walk distance, and echocardiography to detect elevated pulmonary pressures, defined by peak tricuspid regurgitation velocity exceeding two point eight meters per second or tricuspid annular plane systolic excursion below eighteen millimeters. Abnormal diffusing capacity was documented in sixty percent of patients with bronchiectasis compared to seventeen percent in those without it, while echocardiographic signs of pulmonary hypertension occurred in twenty-four percent versus seven percent. Furthermore, mixed obstructive-restrictive spirometric defects were confined exclusively to individuals with bronchiectasis. Comparing pulmonary physiological standards revealed a moderate positive correlation between the pulmonary-specific Hematopoietic Cell Transplant Comorbidity Index and the 2021 American Thoracic Society and European Respiratory Society standards, evidenced by a Kendall tau of zero point five eight. Crucially, all-cause mortality was significantly elevated among patients with bronchiectasis, reaching fifteen percent compared to three percent in unaffected individuals.

Documented clinical management revealed notable variations and modifiable gaps in medical therapy among the thirty-five individuals with bronchiectasis. While eighty percent received nebulized hypertonic saline with short-acting bronchodilators and airway clearance techniques, and eighty-nine percent received immunoglobulin replacement, only twenty-nine percent received high-dose immunoglobulin therapy, defined as at least six hundred milligrams per kilogram monthly for intravenous administration or two hundred milligrams per kilogram weekly for subcutaneous delivery. Furthermore, long-term azithromycin maintenance therapy was documented in only fifty-one percent of patients, despite guideline recommendations supporting macrolide prophylaxis to diminish infectious exacerbations. Importantly, the presence of bronchiectasis directly altered definitive curative therapy decisions in twenty percent of eligible individuals. In one patient with RAG2 deficiency, severe bronchiectasis served as an absolute contraindication to bone marrow transplantation. In other cases, bronchiectasis prompted accelerated transplantation timelines, guided referral for combined lung and stem cell transplantation or isolated lung transplantation prior to gene therapy, or necessitated tailored, busulfan-sparing conditioning regimens using naked anti-c-KIT monoclonal antibodies and irradiation to preserve compromised pulmonary tissue.

The study authors acknowledged important methodological limitations, noting that the cohort was predominantly white, featured an over-representation of severe combined immunodeficiency cases, lacked patients with primary phagocyte defects, and derived from a specialized quaternary referral center where chest computed tomography was clinically indicated, which may yield an upper-bound prevalence estimate. Furthermore, the cross-sectional design precludes establishing causality, and detailed historical data regarding diagnostic delay, smoking history, and environmental exposures were not available for inclusion in regression models. Nevertheless, the findings highlight that bronchiectasis is a frequent, life-threatening complication that develops across diverse genetic immunodeficiencies. The researchers concluded that protocolized pulmonary surveillance—incorporating routine chest computed tomography, complete pulmonary function testing, and non-invasive echocardiography—must be systematically integrated into clinical management across all immunological categories. Early detection and aggressive medical optimization offer an indispensable window of opportunity to arrest or potentially reverse structural damage before irreversible pulmonary impairment narrows definitive curative options.

Subject of Research: Prevalence, clinical predictors, and cardiopulmonary complications of bronchiectasis in patients with inborn errors of immunity

Article Title: Bronchiectasis in Inborn Errors of Immunity: Prevalence, Predictors, and Cardiopulmonary Complications in a Genetically Characterized Cohort

Article References: Marangu-Boore, D., Myint-Hpu, K., Kang, E., Notarangelo, L. D., & Delmonte, O. M. (2026). Bronchiectasis in Inborn Errors of Immunity: Prevalence, Predictors, and Cardiopulmonary Complications in a Genetically Characterized Cohort. Journal of Clinical Immunology, 46(1), Article 92. https://doi.org/10.1007/s10875-026-02044-8

Image Credits: AI Generated

DOI: 10.1007/s10875-026-02044-8

Keywords: Bronchiectasis, Inborn Errors of Immunity, Primary Immunodeficiency, Computed Tomography, RAG1 Deficiency, Severe Combined Immunodeficiency, Pulmonary Complications, Spirometry, Cardiopulmonary Impairment, Immune Dysregulation, Antibody Deficiency, Granulomatous-Lymphocytic Interstitial Lung Disease, Hematopoietic Stem Cell Transplantation, Pulmonary Hypertension, Azithromycin, Immunoglobulin Replacement Therapy, Diffuse Lung Disease

News Source: Ophelia Keating. (November 20, 2026). Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors. Scienmag.

Tags: antibody deficiencyazithromycinbronchiectasisCardiopulmonary Impairmentcomputed tomographyDiffuse Lung DiseaseGranulomatous-Lymphocytic Interstitial Lung Diseasehematopoietic stem cell transplantationimmune dysregulationimmunoglobulin replacement therapyinborn errors of immunityprimary immunodeficiencypulmonary complicationspulmonary hypertensionRAG1 Deficiencysevere combined immunodeficiencyspirometry
Share12Tweet7Share2ShareShareShare1

Related Posts

Evidence Synthesis Challenges Universal Antibiotic Exposure Rules for Gram-Negative Resistance

Evidence Synthesis Challenges Universal Antibiotic Exposure Rules for Gram-Negative Resistance

November 20, 2026
Qualitative Study Identifies Drivers of HPV Vaccine Acceptance Ahead of Ghana Introduction

Qualitative Study Identifies Drivers of HPV Vaccine Acceptance Ahead of Ghana Introduction

November 20, 2026

Computational Study Links miR-130b-3p and NR3C2 Pairing to Kidney Cancer Outcomes

November 20, 2026

Rat Lungworm Infection Drives Divergent Gut Microbiome and Lipid Disruptions in Rodents

November 20, 2026

POPULAR NEWS

  • Chemical and Microbial Feedback Loops Drive Soil Sickness in Medicinal Crops

    Chemical and Microbial Feedback Loops Drive Soil Sickness in Medicinal Crops

    29 shares
    Share 12 Tweet 7
  • National Survey Reveals Significant Digital Gaps Among Groups Facing Oral Health Inequities

    29 shares
    Share 12 Tweet 7
  • Review Evaluates Strategies to Prevent and Treat Mandibular Nerve Injury During Jaw Surgery

    29 shares
    Share 12 Tweet 7
  • Dental Sector Dominates Japan’s Regional Outpatient Dysphagia Rehabilitation Claims

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evidence Synthesis Challenges Universal Antibiotic Exposure Rules for Gram-Negative Resistance

Qualitative Study Identifies Drivers of HPV Vaccine Acceptance Ahead of Ghana Introduction

Computational Study Links miR-130b-3p and NR3C2 Pairing to Kidney Cancer Outcomes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.